Literature DB >> 21387149

O-linked glycosylation leads to decreased thermal stability of interferon alpha 2b as measured by two orthogonal techniques.

Michael James Wilson Johnston1, Grant Frahm, Xuguang Li, Yves Durocher, Mary Alice Hefford.   

Abstract

PURPOSE: Thermal stability is considered an indication of protein fold and conformational stability. We investigate the influence of glycosylation on the thermal stability of interferon alpha 2b (IFN α-2b).
METHODS: Far ultraviolet light circular dichroism spectroscopy (UV CD) and differential scanning calorimetry (DSC) were used to assess the thermal stability of the European Directorate for the Quality of Medicines IFN α-2b reference standards as well as an O-linked glycosylated IFN α-2b produced in human embryonic kidney cells.
RESULTS: Assessment of thermal stability of IFN α-2b and glycosylated IFN α-2b by DSC revealed that non-glycosylated interferon (Tm=65.7 +/- 0.2°C, n=3) was more thermally stable than the glycosylated variant (Tm=63.8 C +/- 0.4°C, n=3). These observations were confirmed with far UV CD (Tm IFN α-2b=65.3 +/- 0.4°C, Tm glycosylated IFN α-2b=63.6 +/- 0.2°C, n=3). Enzymatic deglycosylation of IFN α-2b resulted in improved thermally stability when assessed with far UV CD and DSC.
CONCLUSION: We demonstrate that O-linked glycosylation decreases the thermal stability of IFN α-2b compared to a non-glycosylated variant of the protein.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21387149     DOI: 10.1007/s11095-011-0402-0

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  30 in total

Review 1.  Designing proteins that work using recombinant technologies.

Authors:  T J Graddis; R L Remmele; J T McGrew
Journal:  Curr Pharm Biotechnol       Date:  2002-12       Impact factor: 2.837

Review 2.  Solid lipid nanoparticles as a drug delivery system for peptides and proteins.

Authors:  António J Almeida; Eliana Souto
Journal:  Adv Drug Deliv Rev       Date:  2007-05-01       Impact factor: 15.470

3.  Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta).

Authors:  L Runkel; W Meier; R B Pepinsky; M Karpusas; A Whitty; K Kimball; M Brickelmaier; C Muldowney; W Jones; S E Goelz
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

4.  High resolution crystal structure of a human tumor necrosis factor-alpha mutant with low systemic toxicity.

Authors:  S S Cha; J S Kim; H S Cho; N K Shin; W Jeong; H C Shin; Y J Kim; J H Hahn; B H Oh
Journal:  J Biol Chem       Date:  1998-01-23       Impact factor: 5.157

Review 5.  Expression systems for therapeutic glycoprotein production.

Authors:  Yves Durocher; Michael Butler
Journal:  Curr Opin Biotechnol       Date:  2009-11-04       Impact factor: 9.740

6.  Novel long-lasting interferon alpha derivatives designed by glycoengineering.

Authors:  N Ceaglio; M Etcheverrigaray; R Kratje; M Oggero
Journal:  Biochimie       Date:  2007-11-05       Impact factor: 4.079

Review 7.  Developments in the therapeutic use of erythropoiesis stimulating agents.

Authors:  Wolfgang Jelkmann
Journal:  Br J Haematol       Date:  2008-05       Impact factor: 6.998

8.  A structural basis for interferon-alpha-receptor interactions.

Authors:  Jyothi Kumaran; Lianhu Wei; Lakshmi P Kotra; Eleanor N Fish
Journal:  FASEB J       Date:  2007-05-21       Impact factor: 5.191

9.  Influence of bovine serum albumin on the secondary structure of interferon alpha 2b as determined by far UV circular dichroism spectropolarimetry.

Authors:  Michael J W Johnston; Kayla Nemr; Mary A Hefford
Journal:  Biologicals       Date:  2009-12-23       Impact factor: 1.856

10.  Bioactivity determination of native and variant forms of therapeutic interferons.

Authors:  Louise Larocque; Alex Bliu; Ranran Xu; Abebaw Diress; Junzhi Wang; Rongtuan Lin; Runtao He; Michel Girard; Xuguang Li
Journal:  J Biomed Biotechnol       Date:  2011-03-03
View more
  3 in total

Review 1.  Effects of localized interactions and surface properties on stability of protein-based therapeutics.

Authors:  Brittney J Mills; Jennifer S Laurence Chadwick
Journal:  J Pharm Pharmacol       Date:  2016-11-10       Impact factor: 3.765

2.  A single N-acetylgalactosamine residue at threonine 106 modifies the dynamics and structure of interferon α2a around the glycosylation site.

Authors:  Houman Ghasriani; Pascal J F Belcourt; Simon Sauvé; Derek J Hodgson; Denis Brochu; Michel Gilbert; Yves Aubin
Journal:  J Biol Chem       Date:  2012-11-26       Impact factor: 5.157

3.  Determination of supplier-to-supplier and lot-to-lot variability in glycation of recombinant human serum albumin expressed in Oryza sativa.

Authors:  Grant E Frahm; Daryl G S Smith; Anita Kane; Barry Lorbetskie; Terry D Cyr; Michel Girard; Michael J W Johnston
Journal:  PLoS One       Date:  2014-10-09       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.